LexaGene Announces Collaboration with Texas A&M Veterinary Lab

LexaGene Announces Collaboration with Texas A&M Veterinary Medical Diagnostics Laboratory

BEVERLY, Mass., June 6, 2018 – LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, announced today that it has entered into a collaborative agreement with Texas A&M Veterinary Medical Diagnostics Laboratory. Under this agreement, Texas A&M will provide canine urine samples to LexaGene for testing on the Company’s LX6 prototype for more effective pathogen detection. Prior to sending the samples to LexaGene, Texas A&M will characterize them using conventional diagnostic technologies.

“We are happy to add Texas A&M to our growing list of collaborators that are sending us samples, as this allows us to continue to refine our assays and optimize the LX6 prototype. It is important for us to work with collaborators in different geographic regions to get adequate representation of diseases that thrive in different climates,” said Dr. Jack Regan, LexaGene’s CEO. He continues, “For example, Rickettsia (Rocky Mountain spotted fever) is a tick-borne infection that commonly affects dogs in the Mid- West and Southern states, but is found less often in the Northern states. Conversely, Borrelia burgdorferiand Anaplasma phagocytophilum are common dog pathogens in the Northeast, but are rarely found in the South. For this reason, we need to have collaborators in all corners of the United States to ensure the LX6 is equally effective in each state.”

To be added to the LexaGene email distribution list, please subscribe on the Company website here.

About LexaGene Holdings Inc.

LexaGene is a biotechnology company developing the very first fully automated pathogen detection platform that is open-access, the LX6. The open-access feature will empower end-users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customized pathogen detection. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press ‘go’. The instrument is expected to offer excellent sensitivity, specificity, and breadth of pathogen detection. The instrument will be able to process six samples at a time, in an on- demand fashion, returning results in about 1 hour. The company expects to sell its technology in the food safety, veterinary diagnostics, water quality monitoring, and aquaculture pathogen surveillance markets.

About Texas A & M Veterinary Medical Diagnostics Laboratory

The Texas A&M Veterinary Medical Diagnostic Laboratory is a member of the Texas A&M University System, with a mission to promote animal health and protect agricultural, companion animal and public health in Texas – and beyond – through excellence in veterinary diagnostic services. TVMDL is accredited by the American Association of Veterinary Laboratory Diagnosticians (AAVLD) as a full-service veterinary diagnostic laboratory. TVMDL is also a part of the National Animal Health Laboratory Network (NAHLN), a group of state and regional laboratories performing surveillance testing for high-consequence agricultural and zoonotic pathogens, organized by USDA APHIS. In addition to providing diagnostic services to the food animal industries and companion animal owners, TVMDL is dedicated to developing new diagnostic tools, incorporating state-of-the-art technology, increasing efficiency, and continuing to provide clients with professional expertise to help them solve difficult cases.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors — including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues — that could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


For Marketing inquiries, please email: